PFIZER INC — Director's Dealing 2023

Mar 23, 2023

SEC Form 4/A — Form 4/A

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2023-03-17

Reporting Person: PFIZER INC (10% Owner)
Reporting Person: Pfizer Ventures (US) LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-17	Common Stock, $0.001 par value per share	P	1811594	$2.76	Acquired	5952263	Direct

Footnotes

F1: The securities were issued under that certain first amendment dated March 16, 2023 to the Amended and Restated License Agreement dated October 14, 2022 between the Reporting Person and the Issuer, pursuant to which the Issuer agreed to issue to the Reporting Person such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of the Issuer's common stock on the business day when the closing price of the Issuer's common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day between March 16, 2023 and a date that is within 180 days following October 6, 2022.

F2: On March 17, 2023, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.76 per share.